He currently has a clinical appointment as clinical pharmacist in internal medicine and also has an HIV metabolic syndrome service with the Division of Infectious Diseases at the Dallas VA Medical Center. He is also the program director for the pharmacotherapy specialty residency and has an active research program which focuses on HIV and non-HIV related metabolic syndrome and cardiovascular pharmacotherapy. He is also a registered investigator with the NIH funded Adult AIDS Clinical Trials Group (ACTG) where he is currently serving on the A5209 protocol team that is evaluating the safety and efficacy of ezetimibe (Zetia) in HIV+ patients.

Dr. Busti is currently a member of the Board of Governors for the Accreditation Council for Clinical Lipidology, a Board Member for the National Lipid Association and the Southwest Lipid Association, and serves on the ACLS Continuing Education Planning Committee for the American Heart Association. He is a contributing author to the 2004 and 2006 AHA American Hearth Association's Advanced Cardiac Life Support (ACLS) Guidelines Handbooks and also serves as a pharmacology reviewer for the ACLS guidelines and supporting materials. In 2003 he was appointed by Governor Rick Perry to the State's first Pharmaceutical & Therapeutics Committee and was reappointed for another two-year term in 2005. In May 2005 Dr. Busti was appointed by Executive Commissioner Albert Hawkins to be Chairman to the Drug Utilization Review (DUR) Board for the State of Texas.